Loading company
Biomarin Pharmaceutical Inc.
BMRN · Nasdaq · ·
Next earnings: October 26, 2026
$59.90+0.7%Sep 29 close
- 1M
- -7.4%
- 6M
- +9.3%
- 1Y
- +10.6%
- 5Y
- -23.8%
BMRN · Nasdaq · ·
Next earnings: October 26, 2026
$59.90+0.7%Sep 29 close
Biomarin Pharmaceutical Inc. is scheduled to report next on October 26, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $989.7M | $825.4M | +19.91% |
| Profit | $44.8M | $240.5M | -81.39% |
| Profit per share | $0.23 | $1.23 | -81.30% |
| Free Cash Flow | $139.3M | $168.2M | -17.17% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Biomarin Pharmaceutical Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Biomarin Pharmaceutical Inc. has no earnings call transcript available.